351 related articles for article (PubMed ID: 38474109)
1. Clinical and Preclinical Targeting of Oncogenic Pathways in PDAC: Targeted Therapeutic Approaches for the Deadliest Cancer.
Jiménez DJ; Javed A; Rubio-Tomás T; Seye-Loum N; Barceló C
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474109
[TBL] [Abstract][Full Text] [Related]
2. Novel systemic treatment approaches for metastatic pancreatic cancer.
Dorman K; Heinemann V; Kobold S; von Bergwelt-Baildon M; Boeck S
Expert Opin Investig Drugs; 2022 Mar; 31(3):249-262. PubMed ID: 35114868
[TBL] [Abstract][Full Text] [Related]
3. Autophagy as a therapeutic target in pancreatic cancer.
Piffoux M; Eriau E; Cassier PA
Br J Cancer; 2021 Jan; 124(2):333-344. PubMed ID: 32929194
[TBL] [Abstract][Full Text] [Related]
4. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
5. Targeting hedgehog signaling in pancreatic ductal adenocarcinoma.
Quatannens D; Verhoeven Y; Van Dam P; Lardon F; Prenen H; Roeyen G; Peeters M; Smits ELJ; Van Audenaerde J
Pharmacol Ther; 2022 Aug; 236():108107. PubMed ID: 34999181
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
Tarannum M; Vivero-Escoto JL
Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
[TBL] [Abstract][Full Text] [Related]
7. Translational advances in pancreatic ductal adenocarcinoma therapy.
Hosein AN; Dougan SK; Aguirre AJ; Maitra A
Nat Cancer; 2022 Mar; 3(3):272-286. PubMed ID: 35352061
[TBL] [Abstract][Full Text] [Related]
8. Advancement of NF-κB Signaling Pathway: A Novel Target in Pancreatic Cancer.
Pramanik KC; Makena MR; Bhowmick K; Pandey MK
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30563089
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in drug delivery and targeting for the treatment of pancreatic cancer.
Pramanik N; Gupta A; Ghanwatkar Y; Mahato RI
J Control Release; 2024 Feb; 366():231-260. PubMed ID: 38171473
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapies in pancreatic cancer: Promises and failures.
Barati Bagherabad M; Afzaljavan F; ShahidSales S; Hassanian SM; Avan A
J Cell Biochem; 2019 Mar; 120(3):2726-2741. PubMed ID: 28703890
[TBL] [Abstract][Full Text] [Related]
11. Targeting cancer cell metabolism in pancreatic adenocarcinoma.
Cohen R; Neuzillet C; Tijeras-Raballand A; Faivre S; de Gramont A; Raymond E
Oncotarget; 2015 Jul; 6(19):16832-47. PubMed ID: 26164081
[TBL] [Abstract][Full Text] [Related]
12. The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells.
Xu D; Allsop SA; Witherspoon SM; Snider JL; Yeh JJ; Fiordalisi JJ; White CD; Williams D; Cox AD; Baines AT
Carcinogenesis; 2011 Apr; 32(4):488-95. PubMed ID: 21262926
[TBL] [Abstract][Full Text] [Related]
13. Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance.
Capula M; Perán M; Xu G; Donati V; Yee D; Gregori A; Assaraf YG; Giovannetti E; Deng D
Drug Resist Updat; 2022 Sep; 64():100864. PubMed ID: 36115181
[TBL] [Abstract][Full Text] [Related]
14. Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma.
Liu YH; Hu CM; Hsu YS; Lee WH
Cell Death Dis; 2022 Sep; 13(9):817. PubMed ID: 36151074
[TBL] [Abstract][Full Text] [Related]
15. Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
Bhoopathi P; Mannangatti P; Das SK; Fisher PB; Emdad L
Adv Cancer Res; 2023; 159():285-341. PubMed ID: 37268399
[TBL] [Abstract][Full Text] [Related]
16. TGF-β Inhibitors in Metastatic Pancreatic Ductal Adenocarcinoma.
Alvarez MA; Freitas JP; Mazher Hussain S; Glazer ES
J Gastrointest Cancer; 2019 Jun; 50(2):207-213. PubMed ID: 30891677
[TBL] [Abstract][Full Text] [Related]
17. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions.
Zhang Y; Yang C; Cheng H; Fan Z; Huang Q; Lu Y; Fan K; Luo G; Jin K; Wang Z; Liu C; Yu X
J Hematol Oncol; 2018 Jan; 11(1):14. PubMed ID: 29386069
[TBL] [Abstract][Full Text] [Related]
18. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions.
Giordano G; Pancione M; Olivieri N; Parcesepe P; Velocci M; Di Raimo T; Coppola L; Toffoli G; D'Andrea MR
World J Gastroenterol; 2017 Aug; 23(32):5875-5886. PubMed ID: 28932079
[TBL] [Abstract][Full Text] [Related]
19. State of the art and future directions of pancreatic ductal adenocarcinoma therapy.
Neuzillet C; Tijeras-Raballand A; Bourget P; Cros J; Couvelard A; Sauvanet A; Vullierme MP; Tournigand C; Hammel P
Pharmacol Ther; 2015 Nov; 155():80-104. PubMed ID: 26299994
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic developments in pancreatic cancer.
Hu ZI; O'Reilly EM
Nat Rev Gastroenterol Hepatol; 2024 Jan; 21(1):7-24. PubMed ID: 37798442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
